BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Insight

9 AI Drug Discovery Platforms Built in Asia-Pacific, and What They Have Actually Shipped

For most of the past decade, the only honest answer to the question of whether AI drug discovery works in Asia-Pacific was that nobody could yet know. The ...

August 03, 2026 | Analysis

From Market Access to Long-Term Growth: Rethinking Biopharma Expansion in APAC

BioPharma APAC speaks with Girisan Kariangal, Regional Vice President – Business Development & Alliance Management, Menarini Asia-Pacific, on the...

August 03, 2026 | Interaction

Advancing Freeze-to-Store Workflows for the Next Era of Biopharmaceutical Manufacturing

As biologics, biosimilars, and advanced cell and gene therapies continue to reshape the Asia-Pacific biopharmaceutical landscape, manufac...

August 03, 2026 | Expert Insight

12 Funding Rounds That Show Where APAC Biotech Capital Is Going

There is a version of this story that lists twelve press releases and calls it analysis. This is not that story. Every round below has already been announc...

July 30, 2026 | News

Stopped: The Six-Year Cost of Trials That Never Reached the Finish Line

One infusion, no programme A gene therapy is a one-way door. The vector goes in once, it cannot be taken out, and with current adeno-associated virus tech...

July 28, 2026 | Analysis

How Is Connected Care Reaching Patients at Home?

At the edge of this trend sit simple connected safety devices that keep patients linked to help. To see how that works in practice, learn more about home e...

July 27, 2026 | News

7 Countries Competing to Be the Region’s Next Biomanufacturing Hub

A siting decision for a biomanufacturing facility is one of the most expensive commitments a company makes, and it is made against a fifteen to twenty year...

July 27, 2026 | Analysis

Discount or Validation? Western Pharma’s Appetite for Chinese Assets

There is a number that has stopped being a niche statistic for Asia-watchers and started reshaping where the global drug industry shops. The average upfron...

July 24, 2026 | Analysis

Top 26 Companies Leading Sustainable Biopharma Practices in 2026

Sustainability has stopped being a side conversation in the pharmaceutical industry. In 2026 it sits at the centre of how the sector defines leadership. Th...

July 23, 2026 | Analysis

The Bioreactors Are Ours. The Consumables Are Not.

A new biologics plant is one of the easier things in medicine to photograph. The bioreactors are large and gleaming, the capacity figures are big and round...

July 22, 2026 | Analysis

From Capacity to Capability: The New Race to Lead ASEAN Biomanufacturing

ASEAN is entering a new phase of biopharmaceutical manufacturing, where simply building more capacity will no longer guarantee competitiveness. As ...

July 17, 2026 | Expert Insight

Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence

REPORTAGE / PLASMA SUPPLY THE CHAIR The chair reclines. That is the first thing you notice, walking into a plasma centre in a strip mall on...

July 17, 2026 | Analysis

China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?

THE RESHUFFLE · ANALYSIS On a Monday in June 2026, one line in the United States Federal Register did what two year...

July 16, 2026 | Analysis

The Technology Is Ready. Are APAC’s Regulators?

In a process-development suite in Singapore, or Hyderabad, or Songdo, a perfusion bioreactor can now run for weeks, its output feeding straight into a conn...

July 15, 2026 | Regulatory

Stay Connected